Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)

被引：0
|
作者：
Richardson, Paul [1 ]
Hofmeister, Craig [2 ]
Jakubowiak, Andrzej [3 ]
Zimmerman, Todd M. [5 ]
Spear, Matthew A. [4 ]
Palladino, Michael A. [4 ]
Longenecker, Angie M. [4 ]
Kelly, Susan L. [6 ]
Neuteboom, Saskia [7 ]
Cropp, Gillian F. [4 ]
Lloyd, G. Kenneth [4 ]
Hannah, Alison L. [4 ]
Anderson, Kenneth C. [1 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Ohio State Univ, Med Ctr, Div Hematol, Columbus, OH 43210 USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Nereus Pharmaceut Inc, San Diego, CA USA
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Multiple Myeloma Res Fdn, Norwalk, CT USA
[7] Nereus Pharmaceut Inc, San Diego, CA USA
来源：
BLOOD | 2009年 / 114卷 / 22期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：179 / 179
页数：1
相关论文
共 50 条
  • [31] Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma
    Farag, Sherif S.
    Zhang, Shuhong
    Jansak, Buffy S.
    Wang, Xiaojing
    Kraut, Eric
    Chan, Kenneth
    Dancey, Janet E.
    Grever, Michael R.
    LEUKEMIA RESEARCH, 2009, 33 (11) : 1475 - 1480
  • [32] Phase 1 clinical trial of KOS-953 plus bortezomib (BZ) in relapsed refractory multiple myeloma (MM).
    Chanan-Khan, A.
    Richardson, P.
    Alsina, M.
    Lonial, S.
    Krishnan, A.
    Carroll, M.
    Albitar, M.
    Hannah, A. L.
    Johnson, R. G.
    Anderson, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 137S - 137S
  • [33] Repurposing Leflunomide for Relapsed/Refractory Multiple Myeloma: A Phase 1 Trial
    Rosenzweig, Michael
    Palmer, Joycelynne M.
    Tsai, Ni-Chun
    Buettner, Ralf
    Duarte, Lupe
    Htut, Myo
    Karanes, Chatchada
    Nathwani, Nitya
    Pichiorri, Flavia
    Sahebi, Firoozeh
    Somlo, George
    Synold, Tim
    Wu, Xiwei
    Krishnan, Amrita
    Forman, Stephen J.
    Rosen, Steven T.
    BLOOD, 2017, 130
  • [34] ACTIVITY OF MV-NIS IN A PHASE I TRIAL FOR PATIENTS WITH RELAPSED, REFRACTORY MULTIPLE MYELOMA (MM)
    Dispenzieri, A.
    Lacy, M. Q.
    Laumann, K. M.
    LaPlant, B.
    Dingli, D.
    Gertz, M. A.
    Buadi, F.
    Lowe, V.
    O'Connor, M.
    Leung, N.
    Rajkumar, S. V.
    Kumar, S. K.
    Tong, C.
    Birgin, A.
    Peng, K. W.
    Federspiel, M. J.
    Russell, S. J.
    HAEMATOLOGICA, 2014, 99 : 111 - 111
  • [35] Preclinical evaluation of a novel and orally active proteasome inhibitor as a therapy in relapsed/refractory multiple myeloma
    Chauhan, D
    Catley, L
    Li, G
    Hideshima, T
    Richardson, P
    Palladino, M
    Anderson, KC
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 222S - 222S
  • [36] A Phase 1 Trial of Ruxolitinib, Lenalidomide and Methylprednisolone for Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James R.
    Jennifer, To
    Spektor, Tanya M.
    Turner, Carley
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura V.
    Moss, Robert A.
    Bessudo, Alberto
    Patel, Ravindranath
    Lim, Stephen
    Vescio, Robert
    BLOOD, 2018, 132
  • [37] Phase I clinical trial of IPI-504, a novel, water-soluble Hsp90 inhibitor, in patients with Relapsed/Refractory multiple myeloma (MM).
    Jagannath, S
    Siegel, D
    Richardson, P
    Mazumder, A
    Sydor, J
    Goddard, J
    Walker, J
    Patterson, J
    Normant, E
    Tong, J
    Palombella, V
    Anderson, K
    Adams, J
    Grayzel, D
    BLOOD, 2005, 106 (11) : 719A - 720A
  • [38] Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma
    Kumar, Shaji K.
    Bensinger, William I.
    Zimmerman, Todd M.
    Reeder, Craig B.
    Berenson, James R.
    Berg, Deborah
    Hui, Ai-Min
    Gupta, Neeraj
    Di Bacco, Alessandra
    Yu, Jiang
    Shou, Yaping
    Niesvizky, Ruben
    BLOOD, 2014, 124 (07) : 1047 - 1055
  • [39] Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
    Jagannath, Sundar
    Vij, Ravi
    Kaufman, Jonathan L.
    Martin, Thomas
    Niesvizky, Ruben
    Gabrail, Nashat Y.
    Alsina, Melissa
    Wong, Alvin F.
    Le, Mai H.
    McCulloch, Leanne
    Hannah, Alison L.
    Kauffman, Michael
    Siegel, David Samuel diCapua
    BLOOD, 2010, 116 (21) : 814 - 814
  • [40] Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D
    Townsend, A.
    Padrik, P.
    Mainwaring, P.
    Price, T.
    Catley, L.
    Longenecker, A.
    Palladino, M. A.
    Lloyd, G. K.
    Spear, M. A.
    Millward, M.
    EJC SUPPLEMENTS, 2008, 6 (12): : 74 - 74
12345